Patent ID: 6825174
Filing Date: 2004-11-30
Classification: A61K,C12N

Abstract:
An in vivo method of delivering a pharmaceutical composition to a target polynucleotide comprising administering to the airways of a subject said pharmaceutical composition of a respirable or inhalable particle size of about 0.5 &mgr;m to 500 &mgr;m in size comprising at least one oligonucleotide effective to alleviate hyper-responsiveness to adenosine or increased levels of adenosine, or to alleviate bronchoconstriction, asthma, or lung allergy, wherein the oligonucleotide is 4 to 60 nucleotides long and comprises 15% or less adenosine, wherein said oligonucleotide is antisense to a gene encoding an adenosine receptor associated with bronchoconstriction, and selected from the group consisting of genes encoding an adenosine A1 receptor, adenosine2b receptor or adenosine A3 receptor.